Orexo AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORXOF research report →
About the company
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia.
- CEO
- Nikolaj Sorensen
- IPO
- 2013
- Employees
- 110
- HQ
- Uppsala, SE
Price Chart
- Market Cap
- $73.77M
- P/E
- -3.42
- P/S
- 3.47
- P/B
- 2.34
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- -75.57%
- Op Margin
- -94.37%
- Net Margin
- -101.06%
- ROE
- -228.39%
- ROIC
- -60.99%
- Revenue
- $25.93M · -95.60%
- Net Income
- $-129,474,393 · 36.22%
- EPS
- $-3.74 · 36.50%
- Op Income
- $-346,029,791
- FCF YoY
- 563.89%
- 52W High
- $3.23
- 52W Low
- $2.02
- 50D MA
- $2.11
- 200D MA
- $2.75
- Beta
- 0.89
- Avg Volume
- 52
Get TickerSpark's AI analysis on ORXOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ORXOF coverage
Recent articles, reports, and earnings notes.
No research on ORXOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORXOF report →Similar companies
Peers in the same neighborhood.